Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma
Renal cell carcinoma (RCC), especially clear cell RCC, is generally considered an immunotherapy-responsive cancer. Recently, the prognosis for patients with locally advanced and metastatic RCC has significantly improved with the regulatory approvals of anti-PD-1/PD-L1/CTLA-4 immune checkpoint inhibi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2023.2276629 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849472234886791168 |
|---|---|
| author | Albert Jang Jake N. Lichterman Jeffrey Y. Zhong Jonathan E. Shoag Jorge A. Garcia Tian Zhang Pedro C. Barata |
| author_facet | Albert Jang Jake N. Lichterman Jeffrey Y. Zhong Jonathan E. Shoag Jorge A. Garcia Tian Zhang Pedro C. Barata |
| author_sort | Albert Jang |
| collection | DOAJ |
| description | Renal cell carcinoma (RCC), especially clear cell RCC, is generally considered an immunotherapy-responsive cancer. Recently, the prognosis for patients with locally advanced and metastatic RCC has significantly improved with the regulatory approvals of anti-PD-1/PD-L1/CTLA-4 immune checkpoint inhibitor (ICI)-based regimens. Yet in most cases, RCC will remain initially unresponsive to treatment or will develop resistance over time. Hence, there remains an unmet need to understand what leads to ICI resistance and to develop novel immune and nonimmune treatments to enhance the response to ICIs. In this review, we highlight recently published studies and the latest clinical studies investigating the next generation of immune approaches to locally advanced and metastatic RCC beyond traditional ICIs. These trials include cytokines, gut microbiota-based therapies, novel immune checkpoint agents, vaccines, and chimeric antigen receptor T cells. These agents are being evaluated as monotherapy or in combination with traditional ICIs and will hopefully provide improved outcomes to patients with RCC soon. |
| format | Article |
| id | doaj-art-0b93a94ec1ea4b5bbf631a0170fc8c8a |
| institution | Kabale University |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-0b93a94ec1ea4b5bbf631a0170fc8c8a2025-08-20T03:24:35ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-12-0119310.1080/21645515.2023.2276629Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinomaAlbert Jang0Jake N. Lichterman1Jeffrey Y. Zhong2Jonathan E. Shoag3Jorge A. Garcia4Tian Zhang5Pedro C. Barata6Deming Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USADivision of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USADivision of Solid Tumor Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USADepartment of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USADivision of Solid Tumor Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USADivision of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USADivision of Solid Tumor Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USARenal cell carcinoma (RCC), especially clear cell RCC, is generally considered an immunotherapy-responsive cancer. Recently, the prognosis for patients with locally advanced and metastatic RCC has significantly improved with the regulatory approvals of anti-PD-1/PD-L1/CTLA-4 immune checkpoint inhibitor (ICI)-based regimens. Yet in most cases, RCC will remain initially unresponsive to treatment or will develop resistance over time. Hence, there remains an unmet need to understand what leads to ICI resistance and to develop novel immune and nonimmune treatments to enhance the response to ICIs. In this review, we highlight recently published studies and the latest clinical studies investigating the next generation of immune approaches to locally advanced and metastatic RCC beyond traditional ICIs. These trials include cytokines, gut microbiota-based therapies, novel immune checkpoint agents, vaccines, and chimeric antigen receptor T cells. These agents are being evaluated as monotherapy or in combination with traditional ICIs and will hopefully provide improved outcomes to patients with RCC soon.https://www.tandfonline.com/doi/10.1080/21645515.2023.2276629Immunotherapygut microbiotacytokineinterleukinimmune checkpoint inhibitorvaccine |
| spellingShingle | Albert Jang Jake N. Lichterman Jeffrey Y. Zhong Jonathan E. Shoag Jorge A. Garcia Tian Zhang Pedro C. Barata Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma Human Vaccines & Immunotherapeutics Immunotherapy gut microbiota cytokine interleukin immune checkpoint inhibitor vaccine |
| title | Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma |
| title_full | Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma |
| title_fullStr | Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma |
| title_full_unstemmed | Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma |
| title_short | Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma |
| title_sort | immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma |
| topic | Immunotherapy gut microbiota cytokine interleukin immune checkpoint inhibitor vaccine |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2023.2276629 |
| work_keys_str_mv | AT albertjang immuneapproachesbeyondtraditionalimmunecheckpointinhibitorsforadvancedrenalcellcarcinoma AT jakenlichterman immuneapproachesbeyondtraditionalimmunecheckpointinhibitorsforadvancedrenalcellcarcinoma AT jeffreyyzhong immuneapproachesbeyondtraditionalimmunecheckpointinhibitorsforadvancedrenalcellcarcinoma AT jonathaneshoag immuneapproachesbeyondtraditionalimmunecheckpointinhibitorsforadvancedrenalcellcarcinoma AT jorgeagarcia immuneapproachesbeyondtraditionalimmunecheckpointinhibitorsforadvancedrenalcellcarcinoma AT tianzhang immuneapproachesbeyondtraditionalimmunecheckpointinhibitorsforadvancedrenalcellcarcinoma AT pedrocbarata immuneapproachesbeyondtraditionalimmunecheckpointinhibitorsforadvancedrenalcellcarcinoma |